Nemolizumab (Nemluvio, Galderma) Shows Sustained Improvements in Itch and Lesions in PN
Nemolizumab (Nemluvio, Galderma) is well tolerated and produces sustained and clinically meaningful improvements in symptoms including itch and skin lesions in moderate-to-severe prurigo nodularis for up to two years, according to a new interim analysis of the OLYMPIA long-term extension study.